Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis

Ayalew Tefferi, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Animesh D Pardanani

Research output: Contribution to journalArticle

6 Scopus citations
Original languageEnglish (US)
JournalBritish Journal of Haematology
DOIs
StateAccepted/In press - Jan 1 2017

Keywords

  • Allogeneic
  • Primary myelofibrosis
  • Prognosis
  • Survival
  • Transplant

ASJC Scopus subject areas

  • Hematology

Cite this